Drugs / 20vPnC
20vPnC
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07019909 | Jul 2025 → Jan 2026 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07023081 | Jun 2025 → May 2027 expected | pneumococcal infection | Pfizer | Active not recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT04875533 | Jun 2021 → May 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04887948 | May → Dec 2021 | COVID-19, pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04642079 | Dec 2020 → Apr 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03828617 | Feb → Oct 2019 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03835975 | Feb 2019 → Feb 2020 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03760146 | Dec 2018 → Dec 2019 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06531538 Comparator | Jul 2024 → Feb 2026 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07629440 Comparator | May 2026 → Jun 2029 expected | pneumococcal infection | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT04526574 Comparator | Sep 2020 → Jun 2021 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 18 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-23 | Pfizer | Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older pfizer.com ↗ |
| 2023-04-27 | Pfizer | U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children pfizer.com ↗ |
| 2023-01-06 | Pfizer | U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children pfizer.com ↗ |
| 2022-09-19 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union pfizer.com ↗ |
| 2022-08-12 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants pfizer.com ↗ |
| 2022-02-15 | Pfizer | European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults pfizer.com ↗ |
| 2021-12-17 | Pfizer | CHMP Issues Positive Opinion for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults pfizer.com ↗ |
| 2021-05-24 | Pfizer | Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults pfizer.com ↗ |
| 2021-02-26 | Pfizer | European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older pfizer.com ↗ |
| 2020-12-08 | Pfizer | U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older pfizer.com ↗ |
| 2020-10-21 | Pfizer | Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020 pfizer.com ↗ |
| 2020-05-14 | Pfizer | Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age pfizer.com ↗ |
| 2020-03-18 | Pfizer | Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older pfizer.com ↗ |
| 2019-09-09 | Pfizer | Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants pfizer.com ↗ |
| 2019-04-13 | Pfizer | Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
| 2019-02-28 | Pfizer | Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
| 2018-12-14 | Pfizer | Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
| 2018-09-20 | Pfizer | Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 20vPnC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04526574 ↗ |
| Known as | 20-valent PCV | “The 20-valent PCV (PCV20) was developed to expand protection against pneumococcal disease beyond PCV13.” PMID 34315611 ↗ Jul 2021 |
| Known as | 20-valent pneumococcal conjugate vaccine | “A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease.” PMID 34839993 ↗ Nov 20213“Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)” NCT04526574 ↗ “20-valent pneumococcal conjugate vaccine (20vPnC)” NCT07629440 ↗ “20-valent pneumococcal conjugate vaccine (20vPnC)” NCT06531538 ↗ |
| Known as | PCV20 | “This study evaluated the safety and immunogenicity of coadministration of the 20-valent pneumococcal conjugate vaccine (PCV20) and a booster (third dose) of BNT162b2 COVID-19 vaccine.” PMID 37244809 ↗ May 20235“This study evaluated coadministration of 20-valent pneumococcal conjugate vaccine (PCV20) and an adjuvanted quadrivalent inactivated influenza vaccine (QIV).” PMID 36828719 ↗ Feb 2023 “A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease.” PMID 34839993 ↗ Nov 2021 “The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend protection beyond earlier pneumococcal vaccines.” PMID 38267330 ↗ Jan 2024 “The 20-valent PCV (PCV20) was developed to expand protection against pneumococcal disease beyond PCV13.” PMID 34315611 ↗ Jul 2021 “a 20-valent PCV (PCV20) were evaluated” PMID 34940806 ↗ Aug 2022 |
| Modality | Vaccine | “20-valent pneumococcal conjugate vaccine” NCT03760146 ↗ |
| Route | Intramuscular | “into the left thigh muscle” NCT07629440 ↗ |